This latest funding round brings Senda Biosciences’ total amount raised to $266 million. The funding will be used to finance clinical trials of Senda Biosciences’ programmable medicines platform, according to the Aug. 17 Senda Biosciences news release.
Along with the Mayo Clinic, Flagship Pioneering, Samsung Life Sciences Fund and Stage 1 Ventures also participated in the funding round.
“Senda is pioneering the development of comprehensively programmable medicines with the potential to reach previously inaccessible cells, tissues, and organs,” Senda CEO Guillaume Pfefer, PhD, said. “We believe our approach could transform the lives of patients in need of novel treatments, and so we’re delighted to have attracted support from investors who recognize this potential and its significance.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
